Verve Therapeutics Management
Management criteria checks 2/4
Verve Therapeutics' CEO is Sek Kathiresan, appointed in Jul 2019, has a tenure of 5.33 years. total yearly compensation is $9.32M, comprised of 6.4% salary and 93.6% bonuses, including company stock and options. directly owns 0.8% of the company’s shares, worth $3.57M. The average tenure of the management team and the board of directors is 3 years and 3.5 years respectively.
Key information
Sek Kathiresan
Chief executive officer
US$9.3m
Total compensation
| CEO salary percentage | 6.4% |
| CEO tenure | 5.3yrs |
| CEO ownership | 0.8% |
| Management average tenure | 3yrs |
| Board average tenure | 3.5yrs |
Recent management updates
Recent updates
Verve Therapeutics: An In Vivo Gene Editing 'Moon Shot' For Your Portfolio
Aug 30Earnings Release: Here's Why Analysts Cut Their Verve Therapeutics, Inc. (NASDAQ:VERV) Price Target To US$25.78
Aug 10
We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate
Jul 12Why Verve Therapeutics Deserves A Spot On Your Watchlist
Jun 13Broker Revenue Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher
May 14The Verve Therapeutics, Inc. (NASDAQ:VERV) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 12Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause
Apr 03Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth
Feb 28Verve's Proof-Of-Concept Data Doesn't Inspire Confidence
Feb 13Vectoring In On Verve Therapeutics
Jan 14Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation
Jun 07Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth
Feb 24We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth
Nov 09Verve Therapeutics: Cathie Wood Adds To ARKK
Sep 20Why did Verve Therapeutics stock jump today? Data on high cholesterol candidate
Aug 23Verve Therapeutics falls postmarket on $200M stock offering
Jul 20More CRISPR In Human Subjects
Jul 14Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation
May 11Verve Therapeutics: Early-Stage Biotech With A Large Market
Apr 16Verve Therapeutics (NASDAQ:VERV) Is In A Good Position To Deliver On Growth Plans
Jan 31Verve Therapeutics: Pioneering Cardiovascular Medicine Using The Power Of Gene Editing
Aug 24Verve Therapeutics jumps 75% in its first day of trading
Jun 17CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$197m |
| Jun 30 2024 | n/a | n/a | -US$193m |
| Mar 31 2024 | n/a | n/a | -US$197m |
| Dec 31 2023 | US$9m | US$597k | -US$200m |
| Sep 30 2023 | n/a | n/a | -US$193m |
| Jun 30 2023 | n/a | n/a | -US$192m |
| Mar 31 2023 | n/a | n/a | -US$179m |
| Dec 31 2022 | US$8m | US$571k | -US$157m |
| Sep 30 2022 | n/a | n/a | -US$148m |
| Jun 30 2022 | n/a | n/a | -US$125m |
| Mar 31 2022 | n/a | n/a | -US$137m |
| Dec 31 2021 | US$6m | US$519k | -US$120m |
| Sep 30 2021 | n/a | n/a | -US$113m |
| Jun 30 2021 | n/a | n/a | -US$99m |
| Mar 31 2021 | n/a | n/a | -US$53m |
| Dec 31 2020 | US$2m | US$480k | -US$46m |
Compensation vs Market: Sek's total compensation ($USD9.32M) is above average for companies of similar size in the US market ($USD2.22M).
Compensation vs Earnings: Sek's compensation has increased whilst the company is unprofitable.
CEO
Sek Kathiresan (52 yo)
5.3yrs
Tenure
US$9,319,782
Compensation
Dr. Sekar Kathiresan, M.D., also known as Sek, is Independent Director at Relay Therapeutics, Inc. since July 2022. He is a Founder at Maze Therapeutics, Inc and Director from September 2022. He is Co-Foun...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 5.3yrs | US$9.32m | 0.80% $ 3.6m | |
| CFO & Principal Accounting Officer | 3yrs | US$3.48m | 0.0048% $ 21.6k | |
| President | 6.3yrs | US$3.32m | 0.40% $ 1.8m | |
| Co-Founder | no data | no data | no data | |
| Co-Founder | no data | no data | no data | |
| Co-Founder & Scientific Advisory Board Member | no data | US$7.97k | no data | |
| Co-Founder | no data | no data | no data | |
| Co-Founder & Strategic Advisor | no data | no data | no data | |
| Chief Scientific Officer | less than a year | no data | 0.0021% $ 9.6k | |
| Chief Administrative Officer | 1.8yrs | no data | 0.010% $ 46.0k | |
| Vice President of Investor Relations & Corporate Communications | 3yrs | no data | no data | |
| Executive Director of Human Resources | 1.8yrs | no data | no data |
3.0yrs
Average Tenure
55yo
Average Age
Experienced Management: VERV's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 5.3yrs | US$9.32m | 0.80% $ 3.6m | |
| Co-Founder & Scientific Advisory Board Member | 3.2yrs | US$7.97k | no data | |
| Co-Founder & Independent Chairman of the Board | 6.8yrs | US$451.88k | 0.51% $ 2.3m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.5yrs | US$521.07k | 0% $ 0 | |
| Independent Director | 3.6yrs | US$412.38k | 0% $ 0 | |
| Independent Director | 2.3yrs | US$407.38k | 0% $ 0 | |
| Director | less than a year | no data | no data | |
| Independent Director | 6.3yrs | US$410.88k | 0% $ 0 | |
| Independent Director | 2.4yrs | US$405.88k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data |
3.5yrs
Average Tenure
54.5yo
Average Age
Experienced Board: VERV's board of directors are considered experienced (3.5 years average tenure).